Try a new search

Format these results:

Searched for:

person:shapij06

Total Results:

205


Response to "Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study" [Letter]

Desai, Deesha; Nohria, Ambika; Sikora, Michelle; Mandal, Soutrik; Shapiro, Jerry; Caplan, Avrom S; Garshick, Michael; Lo Sicco, Kristen
PMID: 38499178
ISSN: 1097-6787
CID: 5640192

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity

,; Moussa, Anthony; Bennett, Michaela; Wall, Dmitri; Meah, Nekma; York, Katherine; Bokhari, Laita; Asfour, Leila; Rees, Huw; Abraham, Leonardo Spagnol; Asz-Sigall, Daniel; Basmanav, Fitnat Buket; Bergfeld, Wilma; Betz, Regina C; Bhoyrul, Bevin; Blume-Peytavi, Ulrike; Callender, Valerie; Chitreddy, Vijaya; Combalia, Andrea; Cotsarelis, George; Craiglow, Brittany; Dhurat, Rachita; Donovan, Jeff; Doroshkevich, Andrei; Eisman, Samantha; Farrant, Paul; Ferrando, Juan; Gadzhigoroeva, Aida; Green, Jack; Grimalt, Ramon; Harries, Matthew; Hordinsky, Maria; Irvine, Alan; Jolliffe, Victoria; Kaiumov, Spartak; King, Brett; Lee, Joyce; Lee, Won-Soo; Li, Jane; Lortkipanidze, Nino; McMichael, Amy; Mesinkovska, Natasha Atanaskova; Messenger, Andrew; Mirmirani, Paradi; Olsen, Elise; Orlow, Seth J; Ovcharenko, Yuliya; Piraccini, Bianca Maria; Pirmez, Rodrigo; Rakowska, Adriana; Reygagne, Pascal; Rudnicka, Lidia; Corralo, David Saceda; Senna, Maryanne; Shapiro, Jerry; Sharma, Pooja; Siliuk, Tatiana; Starace, Michela; Suchonwanit, Poonkiat; Takwale, Anita; Tosti, Antonella; Vañó-Galván, Sergio; Visser, Willem I; Vogt, Annika; Wade, Martin; Yip, Leona; Zhou, Cheng; Sinclair, Rodney
IMPORTANCE/UNASSIGNED:Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. OBJECTIVE/UNASSIGNED:To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). EVIDENCE REVIEW/UNASSIGNED:A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022. FINDINGS/UNASSIGNED:Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. CONCLUSIONS AND RELEVANCE/UNASSIGNED:This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure various disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
PMID: 38324292
ISSN: 2168-6084
CID: 5632682

Treatment for Central Centrifugal Cicatricial Alopecia - Delphi Consensus Recommendations

Jackson, Tiaranesha; Sow, Yacine; Dinkins, Jewell; Aguh, Crystal; Ayoade, Katherine Omueti; Barbosa, Victoria; Burgess, Cheryl; Callender, Valerie; Cotsarelis, George; Grimes, Pearl; Harvey, Valerie; Kindred, Chesahna; Lester, Jenna; Lo Sicco, Kristen; Mayo, Tiffany; McMichael, Amy; Oboite, Michelle; Ogunleye, Temitayo; Olsen, Elise; Osei-Tutu, Achiamah; Piliang, Melissa; Senna, Maryanne; Shapiro, Jerry; Tosti, Antonella; Frey, Cheri; Adotama, Prince; Taylor, Susan C
BACKGROUND:There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely. OBJECTIVE:To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA. METHODS:We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed. RESULTS:In Round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in Round 2. After the final Round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus. LIMITATIONS/CONCLUSIONS:This study included only English-speaking, US-based dermatologists and did not consider non-pharmacological therapies. CONCLUSION/CONCLUSIONS:Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.
PMID: 38341148
ISSN: 1097-6787
CID: 5635532

Evaluating the role of COVID-19 vaccines in the landscape of medication-induced alopecia areata [Letter]

Buontempo, Michael G; Alhanshali, Lina; Shapiro, Jerry; Lo Sicco, Kristen
PMID: 37776902
ISSN: 1097-6787
CID: 5613112

Evaluating subjective versus objective measures of changes in hair density using standardized scalp photography

Buontempo, Michael G; Oh, Christina S; Alhanshali, Lina; Klein, Elizabeth J; Karim, Maria; Shapiro, Jerry; Lo Sicco, Kristen
PMID: 37775047
ISSN: 1097-6787
CID: 5613102

Comment on 'Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children'

Buontempo, Michael G; Sicco, Kristen Lo; Shapiro, Jerry
PMID: 37681491
ISSN: 1365-2133
CID: 5613502

Seasonal Trends in Hair Loss: A Big Data Analysis of Google Search Patterns and Their Association with Seasonal Factors [Letter]

Buontempo, Michael G; Ingrassia, Jenne P; Shapiro, Jerry; Sicco, Kristen Lo
PMID: 37471104
ISSN: 1468-3083
CID: 5535962

Understanding perceptions of hair loss in hijab-wearing women: a pilot survey study

Alhanshali, Lina; Bawany, Fatima; Buontempo, Michael G; Shapiro, Jerry; Lo Sicco, Kristen
PMCID:10653569
PMID: 38028023
ISSN: 2352-6475
CID: 5617292

Response to Corona-Rodarte et al.'s "Pressure alopecias: a review" [Comment]

Novice, Madison; Shapiro, Jerry; Lo Sicco, Kristen I
PMID: 37648065
ISSN: 1097-6787
CID: 5609242

Establishing baselines of hair density measurements: Variations across ethnicity, scalp region, and measurement techniques: A systematic review

Buontempo, Michael G; Sperling, Leonard C; Alhanshali, Lina; Shapiro, Jerry; Lo Sicco, Kristen
PMID: 37604232
ISSN: 1097-6787
CID: 5598402